Chlamydia trachomatis is the causative agent of one of the most widespread bacterial sexually transmitted diseases in the world causing an estimated 92 million infections per years with over 11,000 infections last year in BC alone. With treatment failing to stem the spread of infection, a vaccine is widely acknowledged as the only way by which to prevent the suffering and significant infertility caused by C. trachomatis. The project aimed to accelerate the development and commercialization of a novel Chlamydia vaccine by completing mouse studies prior to non-human primate and human trials. A Chlamydia vaccine composition selected through this project is now ready to progress to the next phase of work toward human trials. The project leader is in ongoing talks with two major pharmaceutical companies. PREVENT is also in the process of creating a spin-off company that would allow it to raise funds for further development of the vaccine.